Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

NCT03930498 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Nasopharyngeal Carcinoma

Interventions

DRUG: PD-1 blocking antibody
DRUG: Chemotherapy
RADIATION: IMRT

Sponsor

Sun Yat-sen University